This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vahl, T. P. Articles by D’Alessio, D. A. Search for Related Content PubMed PubMed Citation Articles by Vahl, T. P. Articles by D’Alessio, D. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCAGON

Effects of GLP-1-(7–36)NH₂, GLP-1-(7–37), and GLP-1- (9–36)NH₂ on Intravenous Glucose Tolerance and Glucose-Induced Insulin Secretion in Healthy Humans

Division of Metabolism, Endocrinology, and Nutrition, University of Washington (B.W.P., B.D.F., R.L.P., D.A.D.) and Veterans Affairs Puget Sound Health Care System (R.L.P.), Seattle, Washington 98195; and Division of Endocrinology, University of Cincinnati (T.P.V., D.A.D.), Cincinnati, Ohio 45267

Address all correspondence and requests for reprints to: David D’Alessio, M.D., Division of Endocrinology, University of Cincinnati, ML-0547, Cincinnati, Ohio 45267-0547. E-mail: david.d'alessio{at}uc.edu.

Glucagon-like peptide 1 (GLP-1) is an insulin secretagogue synthesized in the intestine and released in response to meal ingestion. It is secreted primarily in two forms, GLP-1-(7–37) and GLP-1-(7–36)NH₂, both of which bind to a specific GLP-1 receptor (GLP-1r) on the pancreatic ß-cell and augment glucose-stimulated insulin secretion. Once secreted, GLP-1-(7–36)NH₂ is rapidly metabolized to GLP-1-(9–36)NH₂, which is the predominant form of GLP-1 in postprandial plasma because of its relatively slower clearance. Although no clear biological role for GLP-1-(9–36)NH₂ in humans has been identified, recent studies in animals suggest two potential effects: to antagonize the effects of intact GLP-1 and to promote glucose disappearance in peripheral tissues. In the studies reported here we compared the independent effects of GLP-1-(7–36)NH₂, GLP-1-(7–37), and GLP-1-(9–36)NH₂ on parameters of iv glucose tolerance and determined whether GLP-1-(9–36)NH₂ inhibits the insulinotropic actions of GLP-1. Ten healthy subjects underwent 4 separate frequently sampled iv glucose tolerance tests during infusions of GLP-1-(7–37), GLP-1-(7–36)NH₂, GLP-1-(9–36)NH₂, or saline. Results from the iv glucose tolerance test were used to obtain indexes of ß-cell function (acute insulin response to glucose) and iv glucose tolerance (glucose disappearance constant), and the minimal model of glucose kinetics was used to obtain indexes of glucose effectiveness and insulin sensitivity. Compared with control studies, both GLP-1-(7–36)NH₂ and GLP-1-(7–37) significantly increased acute insulin response to glucose, glucose disappearance constant, glucose effectiveness, and glucose effectiveness at zero insulin, but did not change the insulin sensitivity index. In contrast, none of the parameters of glucose tolerance was measurably affected by GLP-1-(9–36) amide. In a second set of experiments, 10 healthy subjects had glucose-stimulated insulin secretion measured during an infusion of GLP-1-(7–36)NH₂ alone or with a simultaneous infusion of GLP-1-(9–36)NH₂ that increased plasma levels approximately 10-fold over those produced by unmetabolized GLP-1. Augmentation of glucose-stimulated insulin secretion by GLP-1-(7–36)NH₂ was not altered by the coadministration of GLP-1-(9–36)NH₂. Based on these results we conclude that GLP-1-(9–36)NH₂ does not regulate insulin release or glucose metabolism in healthy humans.

T.P.V. and B.W.P. contributed equally to this work.

This work was supported by a Clinical Research Award from the American Diabetes Association and Grants R01-DK-54263 and M01-RR-08084.

Abbreviations: AIR_glu, Acute insulin response to glucose; DPP-IV, Dipeptidyl peptidase IV; GEZI, glucose effectiveness at zero insulin; GLP-1, glucagon-like peptide 1; GLP-1r, GLP-1 receptor; -ir, immunoreactivity; IVGTT, iv glucose tolerance test; k_g, glucose disappearance constant; S_G, glucose effectiveness; S_I, insulin sensitivity index.

This article has been cited by other articles:

				R. Abu-Hamdah, A. Rabiee, G. S. Meneilly, R. P. Shannon, D. K. Andersen, and D. Elahi The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1843 - 1852. [Abstract] [Full Text] [PDF]

				D. A. D'Alessio, A. M. Denney, L. M. Hermiller, R. L. Prigeon, J. M. Martin, W. G. Tharp, M. L. Saylan, Y. He, B. E. Dunning, J. E. Foley, et al. Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 81 - 88. [Abstract] [Full Text] [PDF]

				P. B Higgins, J. R Fernandez, W T. Garvey, W. M Granger, and B. A Gower Entero-insular axis and postprandial insulin differences in African American and European American children Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1277 - 1283. [Abstract] [Full Text] [PDF]

				S. C. Woods and D. A. D'Alessio Central Control of Body Weight and Appetite J. Clin. Endocrinol. Metab., November 1, 2008; 93(11_Supplement_1): s37 - s50. [Abstract] [Full Text] [PDF]

				W. J. Lu, Q. Yang, W. Sun, S. C. Woods, D. D'Alessio, and P. Tso The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate Am J Physiol Gastrointest Liver Physiol, November 1, 2007; 293(5): G963 - G971. [Abstract] [Full Text] [PDF]

				T. P. Vahl, M. Tauchi, T. S. Durler, E. E. Elfers, T. M. Fernandes, R. D. Bitner, K. S. Ellis, S. C. Woods, R. J. Seeley, J. P. Herman, et al. Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats Endocrinology, October 1, 2007; 148(10): 4965 - 4973. [Abstract] [Full Text] [PDF]

				D. J. Drucker Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical biology and mechanisms of action Diabetes Care, June 1, 2007; 30(6): 1335 - 1343. [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				J. C. Parker, K S Lavery, N Irwin, B D Green, B Greer, P Harriott, F P M O'Harte, V A Gault, and P R Flatt Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. J. Endocrinol., October 1, 2006; 191(1): 93 - 100. [Abstract] [Full Text] [PDF]

				C. F. Deacon, A. Plamboeck, M. M. Rosenkilde, J. de Heer, and J. J. Holst GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E468 - E475. [Abstract] [Full Text] [PDF]

				J. J. Meier, A. Gethmann, M. A. Nauck, O. Gotze, F. Schmitz, C. F. Deacon, B. Gallwitz, W. E. Schmidt, and J. J. Holst The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1118 - E1123. [Abstract] [Full Text] [PDF]

				M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]

				L. A. Nikolaidis, D. Elahi, Y.-T. Shen, and R. P. Shannon Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2401 - H2408. [Abstract] [Full Text] [PDF]

				M. A. Nauck, B. Baller, and J. J. Meier Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes Diabetes, December 1, 2004; 53(suppl_3): S190 - S196. [Abstract] [Full Text] [PDF]

				C. F. Deacon Therapeutic Strategies Based on Glucagon-Like Peptide 1 Diabetes, September 1, 2004; 53(9): 2181 - 2189. [Abstract] [Full Text] [PDF]

				S. A. Hinke, K. Hellemans, and F. C. Schuit Plasticity of the {beta} cell insulin secretory competence: preparing the pancreatic {beta} cell for the next meal J. Physiol., July 15, 2004; 558(2): 369 - 380. [Abstract] [Full Text] [PDF]

				J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Diabetes, March 1, 2004; 53(3): 654 - 662. [Abstract] [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]